OBJECTIVE: To estimate familial aggregation of rheumatoid arthritis (RA) in 3 large population-representative samples and to test if familial aggregation is affected by rheumatoid factor (RF)/anti-citrullinated protein antibody (ACPA) status, type of relative, sex, and age at onset of RA. METHODS: A register-based nested case-control study was performed in the Swedish total population. Data on patients with RA were ascertained through the nationwide Swedish Patient Register (n = 88,639), the clinical Swedish Rheumatology Quality Register (n = 11,519), and the Epidemiological Investigation of Rheumatoid Arthritis case-control study (n = 2,871). Data on first- and second-degree relatives were obtained through the Swedish Multigeneration Register. Familial risks were calculated using conditional logistic regression. RESULTS: Consistent across data sources, the familial odds ratio for RA was ∼3 in first-degree relatives of RA patients and 2 in second-degree relatives. Familial risks were similar among siblings, parents, and offspring. Familial aggregation was not modified by sex, but was higher in RA patients with early-onset disease and in RF/ACPA-positive RA patients. The observed familial risks were consistent with a heritability of ∼50% for ACPA-positive RA and ∼20% for ACPA-negative RA. CONCLUSION: The pattern of risks suggests that familial factors influence RA in men and women equally and that these factors are of less importance for late-onset RA. Familial factors are more important for seropositive RA, but there is significant familial overlap between seropositive RA and seronegative RA. Even if the familial risk is assumed to be completely due to genetics, the observed risks suggest that heritability of RA is lower than previously reported, in particular for ACPA-negative RA.
OBJECTIVE: To estimate familial aggregation of rheumatoid arthritis (RA) in 3 large population-representative samples and to test if familial aggregation is affected by rheumatoid factor (RF)/anti-citrullinated protein antibody (ACPA) status, type of relative, sex, and age at onset of RA. METHODS: A register-based nested case-control study was performed in the Swedish total population. Data on patients with RA were ascertained through the nationwide Swedish Patient Register (n = 88,639), the clinical Swedish Rheumatology Quality Register (n = 11,519), and the Epidemiological Investigation of Rheumatoid Arthritis case-control study (n = 2,871). Data on first- and second-degree relatives were obtained through the Swedish Multigeneration Register. Familial risks were calculated using conditional logistic regression. RESULTS: Consistent across data sources, the familial odds ratio for RA was ∼3 in first-degree relatives of RApatients and 2 in second-degree relatives. Familial risks were similar among siblings, parents, and offspring. Familial aggregation was not modified by sex, but was higher in RApatients with early-onset disease and in RF/ACPA-positive RApatients. The observed familial risks were consistent with a heritability of ∼50% for ACPA-positive RA and ∼20% for ACPA-negative RA. CONCLUSION: The pattern of risks suggests that familial factors influence RA in men and women equally and that these factors are of less importance for late-onset RA. Familial factors are more important for seropositive RA, but there is significant familial overlap between seropositive RA and seronegative RA. Even if the familial risk is assumed to be completely due to genetics, the observed risks suggest that heritability of RA is lower than previously reported, in particular for ACPA-negative RA.
Authors: Jeffrey A Sparks; Chia-Yen Chen; Xia Jiang; Johan Askling; Linda T Hiraki; Susan Malspeis; Lars Klareskog; Lars Alfredsson; Karen H Costenbader; Elizabeth W Karlson Journal: Ann Rheum Dis Date: 2014-03-31 Impact factor: 19.103
Authors: Jeffrey A Sparks; Maura D Iversen; Rachel Miller Kroouze; Taysir G Mahmoud; Nellie A Triedman; Sarah S Kalia; Michael L Atkinson; Bing Lu; Kevin D Deane; Karen H Costenbader; Robert C Green; Elizabeth W Karlson Journal: Contemp Clin Trials Date: 2014-08-20 Impact factor: 2.226
Authors: Chang-Fu Kuo; Matthew J Grainge; Ana M Valdes; Lai-Chu See; Kuang-Hui Yu; S W Steven Shaw; Shue-Fen Luo; Weiya Zhang; Michael Doherty Journal: Rheumatology (Oxford) Date: 2017-06-01 Impact factor: 7.580
Authors: M Kristen Demoruelle; Kylie K Harrall; Linh Ho; Monica M Purmalek; Nickie L Seto; Heather M Rothfuss; Michael H Weisman; Joshua J Solomon; Aryeh Fischer; Yuko Okamoto; Lindsay B Kelmenson; Mark C Parish; Marie Feser; Chelsie Fleischer; Courtney Anderson; Michael Mahler; Jill M Norris; Mariana J Kaplan; Brian D Cherrington; V Michael Holers; Kevin D Deane Journal: Arthritis Rheumatol Date: 2017-05-02 Impact factor: 10.995
Authors: X Y Zhang; J Y Jin; J He; Y Z Gan; J L Chen; X Z Zhao; J J Liu; X J You; X Li; J P Guo; X F Li; J Li; R Li; Z G Li Journal: Beijing Da Xue Xue Bao Yi Xue Ban Date: 2019-06-18
Authors: Thomas Frisell; Karin Hellgren; Lars Alfredsson; Soumya Raychaudhuri; Lars Klareskog; Johan Askling Journal: Ann Rheum Dis Date: 2014-12-12 Impact factor: 19.103
Authors: Elizabeth W Karlson; Dirkjan van Schaardenburg; Annette H van der Helm-van Mil Journal: Rheumatology (Oxford) Date: 2014-08-04 Impact factor: 7.580